Amicus Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FOLD research report →
Range $13 – $19
Price Chart
About the company
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data.
- CEO
- Bradley L. Campbell
- IPO
- 2007
- Employees
- 499
- HQ
- Philadelphia, PA, US
Get TickerSpark's AI analysis on FOLD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.55B
- P/E
- -163.73
- Fwd P/E
- 40.63
- PEG
- 1.68
- P/S
- 7.17
- P/B
- 16.33
- EV/EBITDA
- 89.56
- Div Yield
- 0.00%
- Gross Margin
- 87.91%
- Op Margin
- 5.17%
- Net Margin
- -4.27%
- ROE
- -12.02%
- ROIC
- -645.68%
Latest fiscal year · YoY change
- Revenue
- $634.21M+20.0%
- Gross Profit
- $553.82M+16.5%
- Op Income
- $34.49M
- Net Income
- $-27,110,000+51.7%
- EPS
- $-0.09+51.2%
- OCF Growth
- +197.8%
- FCF Growth
- +179.7%
- 52W High
- $14.50
- 52W Low
- $5.51
- 50D MA
- $14.40
- 200D MA
- $10.88
- Beta
- 0.48
- RSI (14)
- 72
- Avg Volume
- 4.15M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the FOLD Q3 '25 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 99.2%
- Shares Outstanding
- 314.00M
- Float Shares
- 311.44M
of shares held by institutions
353 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for FOLD, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 33.88M | ▲ 1.35M |
| Vanguard Group Inc | 29.70M | ▲ 168.67K |
| Ubs Group AG | 15.96M | ▲ 10.06M |
| Pentwater Capital Management LP | 14.00M | ▲ 2.50M |
| State Street Corp | 12.89M | ▼ 1.94M |
| Glazer Capital, LLC | 12.72M | ▲ 11.12M |
| Fil Ltd | 12.56M | ▲ 11.60M |
| Goldman Sachs Group Inc | 11.56M | ▲ 5.41M |
| Qube Research & Technologies Ltd | 8.81M | ▲ 4.37M |
| Hbk Investments L P | 8.78M | ▼ 6.47M |
| Geode Capital Management, LLC | 8.54M | ▲ 1.19M |
| Millennium Management LLC | 7.91M | ▲ 4.91M |
Held by 18 ETFs
Biggest fund positions in FOLD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 27, 26 | WHEELER CRAIG A | sell | 84,631 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 30,000 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 16,236 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 19,473 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 18,574 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 36,111 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 45,423 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 30,474 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 42,467 |
| Apr 27, 26 | WHEELER CRAIG A | sell | 74,872 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FOLD coverage
Recent articles, reports, and earnings notes.
Want a deeper read on FOLD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
seekingalpha.com · May 6
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
fool.com · Apr 25
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
seekingalpha.com · Apr 15
SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD
defenseworld.net · Apr 7
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD
defenseworld.net · Apr 6
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
businesswire.com · Mar 26
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD
defenseworld.net · Mar 14
Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD
reuters.com · Mar 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on FOLD?